Wedbush analyst Liana Moussatos maintained a Buy rating on Intercept Pharma (ICPT) on March 8 and set a price target of $251. The company’s shares closed on Friday at $100.94.
According to TipRanks.com, Moussatos has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.5% and a 34.4% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics Inc, Allena Pharmaceuticals Inc, and Catabasis Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intercept Pharma with a $164 average price target, which is a 62.5% upside from current levels. In a report issued on February 28, Raymond James also maintained a Buy rating on the stock with a $187 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $133.74 and a one-year low of $58.03. Currently, Intercept Pharma has an average volume of 939.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
Read More on ICPT:
